-$0.35 EPS Expected for Arbutus Biopharma Corp (ABUS) This Quarter

Wall Street brokerages predict that Arbutus Biopharma Corp (NASDAQ:ABUS) will report earnings of ($0.35) per share for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Arbutus Biopharma’s earnings, with estimates ranging from ($0.36) to ($0.34). Arbutus Biopharma posted earnings of ($0.44) per share in the same quarter last year, which suggests a positive year over year growth rate of 20.5%. The firm is expected to report its next quarterly earnings report on Thursday, August 1st.

According to Zacks, analysts expect that Arbutus Biopharma will report full year earnings of ($1.32) per share for the current financial year, with EPS estimates ranging from ($1.75) to ($0.65). For the next fiscal year, analysts expect that the business will report earnings of ($0.93) per share, with EPS estimates ranging from ($1.18) to ($0.53). Zacks’ EPS averages are a mean average based on a survey of analysts that that provide coverage for Arbutus Biopharma.

Arbutus Biopharma (NASDAQ:ABUS) last posted its quarterly earnings results on Monday, May 6th. The biopharmaceutical company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.16). The firm had revenue of $0.70 million during the quarter, compared to the consensus estimate of $1.18 million. Arbutus Biopharma had a negative net margin of 1,237.92% and a negative return on equity of 95.26%.

Several equities analysts have weighed in on the company. Zacks Investment Research lowered Arbutus Biopharma from a “buy” rating to a “hold” rating in a research note on Friday. Echelon Wealth Partners reissued a “hold” rating on shares of Arbutus Biopharma in a research note on Monday, March 11th. Chardan Capital reissued a “buy” rating and issued a $6.50 target price on shares of Arbutus Biopharma in a research note on Sunday, March 10th. ValuEngine lowered Arbutus Biopharma from a “hold” rating to a “sell” rating in a research note on Wednesday, May 1st. Finally, BidaskClub raised Arbutus Biopharma from a “hold” rating to a “buy” rating in a research note on Tuesday, March 5th. One research analyst has rated the stock with a sell rating, four have given a hold rating and three have assigned a buy rating to the company’s stock. Arbutus Biopharma presently has an average rating of “Hold” and an average price target of $6.25.

Arbutus Biopharma stock opened at $2.35 on Friday. The stock has a market capitalization of $133.60 million, a P/E ratio of -2.30 and a beta of 1.61. Arbutus Biopharma has a 12-month low of $2.29 and a 12-month high of $12.60. The company has a current ratio of 12.75, a quick ratio of 11.50 and a debt-to-equity ratio of 0.06.

A number of large investors have recently added to or reduced their stakes in ABUS. Wells Fargo & Company MN raised its position in shares of Arbutus Biopharma by 46.9% during the third quarter. Wells Fargo & Company MN now owns 68,063 shares of the biopharmaceutical company’s stock worth $644,000 after purchasing an additional 21,737 shares during the period. Bank of New York Mellon Corp raised its position in shares of Arbutus Biopharma by 129.9% during the third quarter. Bank of New York Mellon Corp now owns 191,857 shares of the biopharmaceutical company’s stock worth $1,813,000 after purchasing an additional 108,398 shares during the period. BlackRock Inc. raised its position in shares of Arbutus Biopharma by 1.3% during the third quarter. BlackRock Inc. now owns 2,422,221 shares of the biopharmaceutical company’s stock worth $22,891,000 after purchasing an additional 31,078 shares during the period. MetLife Investment Advisors LLC acquired a new stake in shares of Arbutus Biopharma during the third quarter worth about $270,000. Finally, AQR Capital Management LLC raised its position in shares of Arbutus Biopharma by 142.3% during the third quarter. AQR Capital Management LLC now owns 46,576 shares of the biopharmaceutical company’s stock worth $440,000 after purchasing an additional 27,354 shares during the period. 42.59% of the stock is currently owned by hedge funds and other institutional investors.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. Its HBV product pipeline consists of AB-506, a capsid inhibitor that has shown improved potency and pharmacokinetics over its first generation capsid inhibitor; and AB-423, which is in pre-clinical studies.

Featured Article: Analyst Ratings Trading

Get a free copy of the Zacks research report on Arbutus Biopharma (ABUS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Arbutus Biopharma (NASDAQ:ABUS)

Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply